Physician preferences for non-metastatic castration-resistant prostate cancer treatment

BACKGROUND: Recent approvals of second-generation androgen receptor inhibitors (SGARIs) have changed the treatment landscape for non-metastatic castration-resistant prostate cancer (nmCRPC). These SGARIs have similar efficacy but differ in safety profiles. We used a discrete choice experiment to exp...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Urol
Autors principals: Srinivas, Sandy, Mohamed, Ateesha F., Appukkuttan, Sreevalsa, Botteman, Marc, Ng, Xinyi, Joshi, Namita, Horodniceanu, Erica, Waldeck, A. Reginald, Simmons, Stacey J
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310549/
https://ncbi.nlm.nih.gov/pubmed/32571276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12894-020-00631-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars